Clincosm LogoSign in Get a demo

A Comparative Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Sponsor
Astellas Pharma Inc (Industry)
Overall Status
Completed
CT.gov ID
NCT01057407
Collaborator
(none)
110
Enrollment
3
Locations
2
Arms
8
Duration (Months)
36.7
Patients Per Site
4.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a multi-center, open-labeled study to examine the non-inferiority of ASP1585 to sevelamer hydrochloride in chronic kidney disease patients with hyperphosphatemia on hemodialysis.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
110 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 3, Multicenter, Open-label, Sevelamer Hydrochloride-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia on Hemodialysis
Study Start Date :
Jan 1, 2010
Actual Primary Completion Date :
Sep 1, 2010
Actual Study Completion Date :
Sep 1, 2010

Arms and Interventions

Arm Intervention/Treatment
Experimental: ASP group

Drug: ASP1585
oral
Other Names:
  • ILY101
  • AMG223

    		•
    Active Comparator: Sevelamer group

    Drug: Sevelamer hydrochloride
    oral
    Other Names:
  • Renagel
  • phosbloc

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Serum phosphorus level at the end of treatment [After 12-week or at the treatment discontinuation]

    Secondary Outcome Measures

    1. Change in serum phosphorus level [After 12-week or at the end of treatment]

    2. Time-course changes in serum phosphorus levels [During Treatment]

    3. Changes in serum Ca x P [During treatment]

    4. Changes in intact PTH levels [During Treatment]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Chronic kidney disease patients on hemodialysis

    • Hyperphosphatemia

    • Patients on a phosphate binder or phosphate lowering drug for 28 days or longer, and that, those for whom the dose has not been changed within 28 days

    • Written informed consent

    Exclusion Criteria:

    • Patients with gastrointestinal surgery or enterectomy

    • Patients with severe cardiac diseases

    • Patients with severe constipation or diarrhea

    • Patients with a history or complication of malignant tumors

    • Patients with uncontrolled hypertension

    • Patients treated with parathyroid intervention

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Chubu Japan
    2 Kantou Japan
    3 Kyusyu Japan

    Sponsors and Collaborators

    • Astellas Pharma Inc

    Investigators

    • Study Chair: Use Central Contact, Astellas Pharma Inc

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Astellas Pharma Inc
    ClinicalTrials.gov Identifier:
    NCT01057407
    Other Study ID Numbers:
    • 1585-CL-0003
    First Posted:
    Jan 27, 2010
    Last Update Posted:
    May 4, 2015
    Last Verified:
    Apr 1, 2015
    Keywords provided by Astellas Pharma Inc
    Hyperphosphatemia
    hemodialysis
    CKD
    ASP1585
    Additional relevant MeSH terms:
    Kidney Diseases
    Renal Insufficiency, Chronic
    Renal Insufficiency
    Hyperphosphatemia
    Sevelamer

    Study Results

    No Results Posted as of May 4, 2015